Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
BCYC
Stock Latest News
The Fly
Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies
8h ago
BCYC
Premium
Ratings
Analyst Initiates Buy Rating on Nuzetide Developer, Citing Differentiated Efficacy in Urothelial Cancer and Advancing Pancreatic Cancer Program
10h ago
BCYC
Premium
The Fly
Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c)
15h ago
BCYC
Premium
Ratings
Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation
11d ago
BCYC
Premium
The Fly
Bicycle Therapeutics announces updates from EphA2 pipeline at AACR meeting
11d ago
BCYC
Premium
Company Announcements
Bicycle Therapeutics Advances EphA2 Oncology Pipeline With New Data
11d ago
8K
BCYC
Premium
The Fly
Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley
23d ago
BCYC
Premium
Ratings
Bicycle Therapeutics: Portfolio Refocus and Cost Cuts Extend Cash Runway, Strengthening Risk‑Reward and Supporting Buy Rating
1M ago
BCYC
Premium
The Fly
Bicycle Therapeutics price target lowered to $7 from $11 at RBC Capital
1M ago
BCYC
Premium
The Fly
Bicycle Therapeutics price target lowered to $36 from $44 at Oppenheimer
1M ago
BCYC
Premium
The Fly
Bicycle Therapeutics price target lowered to $8 from $12 at Citizens
1M ago
BCYC
Premium
The Fly
Bicycle Therapeutics price target lowered to $8 from $10 at Truist
1M ago
BCYC
Premium
The Fly
Bicycle Therapeutics reports Q4 EPS (29c), consensus (95c)
1M ago
BCYC
Premium
Pre-Earnings
BCYC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
BCYC
Premium
The Fly
Bicycle Therapeutics CFO Alethia Young steps down, Travis Thompson succeeds
3M ago
BCYC
Premium
The Fly
Bicycle Therapeutics CMO Eric Westin retires, Michael Method succeeds
3M ago
BCYC
Premium
The Fly
Bicycle Therapeutics names Michael Skynner chief scientific officer
3M ago
BCYC
Premium
Company Announcements
Bicycle Therapeutics Sets 2026 Oncology and Radiopharma Priorities
4M ago
8K
BCYC
Premium
The Fly
Bicycle signs 15-year uranium contract with UK Nuclear Decommissioning Authority
5M ago
BCYC
Premium
The Fly
Bicycle Therapeutics initiated with a Hold at Truist
5M ago
BCYC
Premium
Ratings
Buy Rating for Bicycle Therapeutics: Strong Upside Potential Amid Clinical and Financial Developments
6M ago
BCYC
Premium
The Fly
Bicycle Therapeutics price target raised to $12 from $10 at Citizens JMP
6M ago
BCYC
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
